Investigators from Shanghai, China, report responses above 90% by using levantinib and tislelizumab to treat patients with a ...

New antibody AHA-1031 shows potential in treating non small cell lung cancer resistant to immunotherapy, offering new hope.

Lung cancer is one of the leading causes of cancer mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for about ...

A research team has developed a multi-medium approach (MMA) to identify reproducible volatile organic compounds (VOCs) in ...

The following is a summary of “Transcriptional regulatory network analysis identifies GRN as a key regulator bridging chemotherapy and immunotherapy response in small cell lung cancer,” published in ...

Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

Researchers from the Francis Crick Institute have found that some particularly aggressive lung cancer cells can develop their ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Diagnosed with stage 3B lung cancer in 2018, I joined a support group where I met Jim and Melanie, and learned about Jim's ...

Using preoperative chest CT scans, researchers identified novel preoperative biomarkers for lung cancer recurrence ...

Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift ...